NXGLW

Contract Manufacturing - Played a pivotal role in growth with increased demand from existing customers and new global corporations. Relationship with Cintas remains strong with SilverSeal in their wound care kits. Institutional review board study on hydrogels for laser hair removal near publication. Partnership with iRhythm for hydrogels in Zio ECG heart monitoring system, anticipating first orders this quarter. New customer pipeline robust with launches approaching. ### Consumer Products - Revenue stable year over year and sequentially. Logistical delays resolved, expecting strong Q4 including new products. Silly George's lip gloss launch went well, Kenco Derm expanding into eczema solutions, Metagel product line expansion including Silver Seal wound and burn kit. Partnership with Stada amended, soft launching Gluticin in December with more products in 2026, and $1 million non-dilutive financing from Stada.

- Fourth quarter revenues expected to increase sequentially, with Q4 being a record quarter. ### - Full year 2025 revenue guidance between $12 and $12.5 million, with higher end dependent on strong consumer products holiday season. ### - Adjusted EBITDA loss narrowed to $354,000 in Q3 and expected to narrow further to close to breakeven in Q4.

For the third quarter of 2025, the contract manufacturing segment generated revenue of $907,000, a slight increase year over year and sequentially. The consumer products segment had stable year-over-year and sequential revenue, with logistical delays affecting some product launches but expecting a strong fourth quarter.

- Unforeseen logistical delays affected product launches in the third quarter. ### - Uncertainty regarding AbbVie's plans with the recycling device as AbbVie took an impairment charge and details are unclear.

Q: Could you elaborate more on the logistical delays and how much sales they ended up affecting?

A: The total delay varied by product, impacted existing products not severely but affected lip gloss launch, likely $100,000 to $200,000 in sales.

Q: What gives confidence in the full year guidance, especially the top end?

A: Fourth quarter expected to be strong with contract manufacturing growth, but consumer products holiday season is the wildcard.

Q: What's going on with AbbVie and the restarting device?

A: Frustrating situation as AbbVie sent conflicting signals with an email about a PO then taking an impairment charge, unclear status.

Q: What's the current order book like from contract manufacturing?

A: Strong, with existing customers continuing to order and a robust pipeline of potential new customers.

Q: Expectation of positive EBITDA by end of year?

A: Expecting to be close to positive, dependent on strong consumer products quarter.